Prostate Cancer

The phase 2 trial has shown encouraging safety and efficacy results for carotuximab and apalutamide in patients with mCRPC.

The trial enrolled over 700 high-risk participants across 20 clinical trial sites in Taiwan.

The conversation tackles testosterone therapy in men with prostate cancer, a complex and sometimes controversial issue.

Recent data suggests a lack of knowledge among primary care providers on the value of prostate specific antigen testing, particularly for patients in high-risk groups.

According to the authors, these findings suggest that biparametric MRI could become the new standard of care for prostate cancer diagnosis.

Both experts agreed that although the details shift by condition, the core structure of patient-centered decision-making remains constant.

The registrational trial is aiming to expand the indications for Illuccix and Gozellix to include use in prostate cancer diagnosis.

"As urologists, we should be proactive and creative as we find new ways to attract, retain and train the next generation," writes Michael S. Cookson, MD, MMHC, FACS.

Patients will be enrolled in the study through clinical trial sites in the US, with additional international sites to follow.

The episode also underscores the role of artificial intelligence in prostate imaging.

Rana R. McKay, MD, FASCO, highlights notable takeaways from the COMRADE trial, assessing the combination of olaparib plus radium-223 in CRPC.

Surprisingly, the Mediterranean diet—which has shown benefits in other areas of health—was not consistently linked to prostate cancer risk reduction.

The biomarker panel demonstrated the ability to detect prostate cancer even in men with prostate-specific antigen levels in the normal range.

The report showed rising incidence rates and a slowing of mortality declines in addition to persistent racial disparities.

Both experts stress that the framework is not intended to overhaul physicians’ communication styles but rather to highlight overlooked areas.

A recap of the FDA submissions and regulatory decisions in urology from August 2025.

Many clinicians do not explain how the consultation will unfold or clearly define the respective roles of physician and patient.

The approval is supported by findings from an open-label, single-arm, phase 3 trial.

Rana R. McKay, MD, FASCO, details the key efficacy and safety findings from the phase 2 COMRADE trial.

The findings highlight a lack of awareness on the signs and symptoms of prostate cancer, as well as common misconceptions about testicular cancer.

Timothy D. McClure, MD, offers his thoughts on how future advancements will inform the role for focal therapy in prostate cancer.

The findings were derived from the multicenter, prospective, phase 3 STAMPEDE trial.

Christopher Weight, MD, MS, discusses the current state and directions of AI and prostate cancer.

“This shows that AI analysis of routine biopsies can detect subtle signs indicating clinically significant prostate cancer before it becomes obvious to a pathologist," says Carolina Wählby, PhD.

Darolutamide plus ADT has also been approved in the US as well as in the European Union.